Suppr超能文献

米索前列醇与硫糖铝及安慰剂预防阿司匹林所致胃和十二指肠溃疡的盲法内镜对比研究

A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration.

作者信息

Lanza F, Peace K, Gustitus L, Rack M F, Dickson B

机构信息

Houston Institute for Clinical Research, Sharpstown General Hospital, Houston, Texas.

出版信息

Am J Gastroenterol. 1988 Feb;83(2):143-6.

PMID:3124604
Abstract

In a series of previous studies, we showed that misoprostol protects the gastric and duodenal mucosae against ulceration seen with the administration of both aspirin and the nonsteroidal antiinflammatory drug tolmetin. The purpose of this study was to confirm, in addition, that misoprostol protects the mucosae against aspirin-induced damage and, for the first time, to compare its cytoprotective properties with those of sucralfate. Thirty healthy volunteers were randomized into three equal groups receiving either misoprostol 200 micrograms, sucralfate 1 g, or placebo, co-administered with 650 mg of aspirin, four times a day for 7 days. All subjects had endoscopically normal mucosae on entry and were reendoscoped 2 h after a single final dose on day 7. The mucosae were graded on a 0-4 scale as follows: 0 = normal, 1 = single hemorrhage or erosion, 2 = 2-10 hemorrhages or erosions, 3 = 11-25 hemorrhages or erosions, 4 = more than 25 hemorrhages or erosions or an invasive ulcer of any size. Utilizing a previously established criterion of a score of 2 or less as a clinically significant degree of protection to the gastric mucosae, we found that the success rate for misoprostol was 100% (10/10), compared to 20% (2/10) for sucralfate and 0% (0/10) for placebo. Misoprostol was statistically significantly superior to both sucralfate (p = 0.0001) and placebo (p = 0.00001), with 95% confidence intervals on the difference in success rates between misoprostol and sucralfate and between misoprostol and placebo of (44%; 100%) and (61%; 100%), respectively. In the duodenum, nine of 10 subjects taking misoprostol showed no damage (0 grade), whereas this was seen in only five sucralfate and three placebo patients. Misoprostol was significantly superior to placebo (p = 0.020) and marginally superior to sucralfate (p = 0.141) with confidence intervals of (29%; 91%) and (-5%; 67%), respectively. Adverse experiences were minor and did not differ in the three groups.

摘要

在一系列先前的研究中,我们发现米索前列醇可保护胃和十二指肠黏膜,防止阿司匹林和非甾体抗炎药托美丁所致的溃疡。此外,本研究旨在证实米索前列醇可保护黏膜免受阿司匹林诱导的损伤,并首次将其细胞保护特性与硫糖铝进行比较。30名健康志愿者被随机分为三组,每组人数相等,分别接受200微克米索前列醇、1克硫糖铝或安慰剂,同时每日4次服用650毫克阿司匹林,共服用7天。所有受试者在入组时内镜检查黏膜均正常,并在第7天单次服用最后一剂药物2小时后再次接受内镜检查。黏膜按0 - 4级进行分级,具体如下:0级 = 正常;1级 = 单个出血或糜烂;2级 = 2 - 10处出血或糜烂;3级 = 11 - 25处出血或糜烂;4级 = 超过25处出血或糜烂或任何大小的侵袭性溃疡。利用先前确立的以2分及以下作为对胃黏膜具有临床显著保护程度的标准,我们发现米索前列醇的成功率为100%(10/10),硫糖铝为20%(2/10),安慰剂为0%(0/10)。米索前列醇在统计学上显著优于硫糖铝(p = 0.0001)和安慰剂(p = 0.00001),米索前列醇与硫糖铝以及米索前列醇与安慰剂之间成功率差异的95%置信区间分别为(44%;100%)和(61%;100%)。在十二指肠中,服用米索前列醇的10名受试者中有9名未出现损伤(0级),而硫糖铝组仅有5名、安慰剂组仅有3名受试者未出现损伤。米索前列醇显著优于安慰剂(p = 0.020),略优于硫糖铝(p = 0.141),置信区间分别为(29%;91%)和(-5%;67%)。三组的不良事件均较轻微,且无差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验